Renal toxicity of the nonsteroidal anti-inflammatory drugs

Since we launched our website in 2014, there has been a significant amount of new research published that indicates that gadolinium is being deposited in the brain.  As a result of those findings, on July 27, 2015, the FDA released a new Safety Announcement regarding Gadolinium-Based Contrast Agents.   The FDA is investigating the risk of brain deposits of gadolinium following repeated use of GBCAs for magnetic resonance imaging (MRI).  While GBCAs are being investigated, they can still be administered; however, health care professionals have been cautioned to limit GBCA use to circumstances in which the use of contrast is deemed necessary.

After surgical excision, up to 30% of patients with localized tumors experience relapse. The lung is the most common site of distant recurrence, seen in 50% to 60% of patients. The median time to relapse after surgery is approximately 2 years, with most relapses occurring within 5 years. Interferon alpha and high-dose interleukin-2 (IL-2) have been tested as adjuvant treatments following resection of stage 1-2 kidney cancer. However, no benefit has been seen in randomized trials. 29,30 Observation remains standard care after nephrectomy, and eligible patients should be offered enrollment in randomized clinical trials.

Renal toxicity of the nonsteroidal anti-inflammatory drugs

renal toxicity of the nonsteroidal anti-inflammatory drugs

Media:

renal toxicity of the nonsteroidal anti-inflammatory drugsrenal toxicity of the nonsteroidal anti-inflammatory drugsrenal toxicity of the nonsteroidal anti-inflammatory drugsrenal toxicity of the nonsteroidal anti-inflammatory drugsrenal toxicity of the nonsteroidal anti-inflammatory drugs